A Corporation Perspective on Developing Bacteriophage Therapies in 3 Questions: What Do We Know, What is New, What Remains to be Determined?

Time: 9:30 am
day: Day One


  • What is known: how phage therapeutics fit into existing regulatory frameworks
  • What is new: manufacturing challenges for pathogenic producer cell lines and product safety
  • What regulatory approaches remain to be determined: e.g. novel clinical trial approaches, long term safety, product evolution to keep in front of phage resistance